Benjamin Burnett
Stock Analyst at Wells Fargo
(2.34)
# 2,756
Out of 5,030 analysts
73
Total ratings
50.98%
Success rate
-2.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Assumes: Overweight | $163 | $127.94 | +27.40% | 1 | Sep 3, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $31 | $23.02 | +34.67% | 1 | Sep 3, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Equal-Weight | $16 | $15.22 | +5.12% | 1 | Sep 3, 2025 | |
| ALKS Alkermes | Initiates: Overweight | $44 | $30.26 | +45.41% | 1 | Sep 3, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.47 | +104.08% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $69.15 | -29.14% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $86.95 | +40.31% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $25.98 | +165.59% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $29.26 | +132.40% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.23 | +273.98% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $14.81 | +288.25% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $6.90 | +11,204.35% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $48 | $41.63 | +15.30% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $54.10 | +18.30% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $89.94 | +4.51% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $1.83 | +118.58% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.00 | +150.00% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.18 | +1,046.79% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $57.77 | +523.16% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.64 | +2,402.74% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Sep 3, 2025
Assumes: Overweight
Price Target: $163
Current: $127.94
Upside: +27.40%
Centessa Pharmaceuticals
Sep 3, 2025
Initiates: Overweight
Price Target: $31
Current: $23.02
Upside: +34.67%
Avadel Pharmaceuticals
Sep 3, 2025
Initiates: Equal-Weight
Price Target: $16
Current: $15.22
Upside: +5.12%
Alkermes
Sep 3, 2025
Initiates: Overweight
Price Target: $44
Current: $30.26
Upside: +45.41%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.47
Upside: +104.08%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $69.15
Upside: -29.14%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $86.95
Upside: +40.31%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $25.98
Upside: +165.59%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $29.26
Upside: +132.40%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.23
Upside: +273.98%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $14.81
Upside: +288.25%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $6.90
Upside: +11,204.35%
Sep 3, 2025
Assumes: Overweight
Price Target: $48
Current: $41.63
Upside: +15.30%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $54.10
Upside: +18.30%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $89.94
Upside: +4.51%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $1.83
Upside: +118.58%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.00
Upside: +150.00%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.18
Upside: +1,046.79%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $57.77
Upside: +523.16%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.64
Upside: +2,402.74%